{"id":37826,"date":"2025-07-23T15:40:13","date_gmt":"2025-07-23T07:40:13","guid":{"rendered":"https:\/\/flcube.com\/?p=37826"},"modified":"2025-07-23T15:40:14","modified_gmt":"2025-07-23T07:40:14","slug":"ascentage-pharma-collaborates-with-major-chinese-firms-to-commercialize-lisaftoclax","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37826","title":{"rendered":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax"},"content":{"rendered":"\n

China-based Ascentage Pharma (NASDAQ: AAPG<\/a>, HKG: 6855<\/a>) announced today that it has entered into cooperation agreements with Sinopharm Group Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd, and China Resources Tianjin Pharmaceutical Co., Ltd. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China’s first approved domestic innovative Bcl-2 inhibitor.<\/p>\n\n\n\n

About Lisaftoclax<\/strong>
Lisaftoclax is a novel, orally administered, selective Bcl-2 inhibitor independently developed by Ascentage Pharma. It received marketing approval in China on July 8 for treating adult patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who have received at least one prior systemic therapy, including a BTK inhibitor.<\/p>\n\n\n\n

Strategic Importance<\/strong>
These strategic cooperation agreements are a crucial part of Ascentage Pharma’s commercialization strategy. They initiate multi-faceted collaborations to explore suitable models for pre-launch services, logistics, national distribution, market access to end hospitals and pharmacies, and new retail expansion. The goal is to accelerate the nationwide commercialization of Lisaftoclax efficiently, enabling this innovative Chinese drug to benefit more patients sooner.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation…<\/p>\n","protected":false},"author":1,"featured_media":37828,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[200,4240,985,3273,2311],"class_list":["post-37826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ascentage-pharma","tag-china-resources-tianjin-pharmaceutical","tag-hkg-6855","tag-nasdaq-aapg","tag-sinopharm-group-company"],"yoast_head":"\nAscentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation agreements with Sinopharm Holdings, Shanghai Pharma Holdings, and China Resources Tianjin. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China's first approved domestic innovative Bcl-2 inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37826\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax\" \/>\n<meta property=\"og:description\" content=\"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation agreements with Sinopharm Holdings, Shanghai Pharma Holdings, and China Resources Tianjin. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China's first approved domestic innovative Bcl-2 inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37826\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-23T07:40:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T07:40:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax\",\"datePublished\":\"2025-07-23T07:40:13+00:00\",\"dateModified\":\"2025-07-23T07:40:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826\"},\"wordCount\":199,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2309.webp\",\"keywords\":[\"Ascentage Pharma\",\"China Resources Tianjin Pharmaceutical\",\"HKG: 6855\",\"NASDAQ: AAPG\",\"Sinopharm Group Company\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37826#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37826\",\"name\":\"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2309.webp\",\"datePublished\":\"2025-07-23T07:40:13+00:00\",\"dateModified\":\"2025-07-23T07:40:14+00:00\",\"description\":\"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation agreements with Sinopharm Holdings, Shanghai Pharma Holdings, and China Resources Tianjin. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China's first approved domestic innovative Bcl-2 inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37826\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2309.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2309.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37826#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax - Insight, China's Pharmaceutical Industry","description":"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation agreements with Sinopharm Holdings, Shanghai Pharma Holdings, and China Resources Tianjin. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China's first approved domestic innovative Bcl-2 inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37826","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax","og_description":"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation agreements with Sinopharm Holdings, Shanghai Pharma Holdings, and China Resources Tianjin. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China's first approved domestic innovative Bcl-2 inhibitor.","og_url":"https:\/\/flcube.com\/?p=37826","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-23T07:40:13+00:00","article_modified_time":"2025-07-23T07:40:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37826#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37826"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax","datePublished":"2025-07-23T07:40:13+00:00","dateModified":"2025-07-23T07:40:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37826"},"wordCount":199,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37826#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp","keywords":["Ascentage Pharma","China Resources Tianjin Pharmaceutical","HKG: 6855","NASDAQ: AAPG","Sinopharm Group Company"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37826#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37826","url":"https:\/\/flcube.com\/?p=37826","name":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37826#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37826#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp","datePublished":"2025-07-23T07:40:13+00:00","dateModified":"2025-07-23T07:40:14+00:00","description":"China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation agreements with Sinopharm Holdings, Shanghai Pharma Holdings, and China Resources Tianjin. These partnerships aim to combine the strengths of each party in R&D innovation, market development, and channel management to jointly advance the commercialization of Lisaftoclax (generic name: lisaftoclax), China's first approved domestic innovative Bcl-2 inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37826#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37826"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37826#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp","width":1080,"height":608,"caption":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37826#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2309.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37826"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37826\/revisions"}],"predecessor-version":[{"id":37829,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37826\/revisions\/37829"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37828"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}